usertwitterfacebookinstagramsearchchess-ratingclock-ratingflash-ratingflashcalendar-modalpencil-modal
logologo
International Chess Federation
beta
user
Monday, 27 Sep 2021 07:30
FIDE and Establishment Labs announce landmark sponsorship agreement for women's chess

September 27, 2021 - The International Chess Federation (FIDE) announced a landmark partnership agreement with Establishment Labs, a global medical technology company. The partnership is the first-ever corporate sponsorship agreement specifically aimed at supporting women's chess events. The agreement will continue through 2022, a year that has been designated by FIDE as "The Year of Women in Chess". 

Establishment Labs is a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction. The company has developed a comprehensive portfolio of advanced breast products, branded as Motiva®, that include a number of innovative and patented features designed to deliver improved clinical and aesthetic outcomes. Establishment Labs is listed on the NASDAQ exchange under the ticker ESTA and its products are available in over 80 countries around the world.

"Establishment Labs has championed women's health and wellness for over a decade and our partnership with FIDE to promote professional women's chess is the natural embodiment of all that we stand for as an organization," said Juan José Chacón Quirós, Founder and CEO of Establishment Labs. "We are proud to support these exceptional women and are continually inspired by their achievements and determination." 

Among the events sponsored by Establishment Labs will be the FIDE Women's Candidates Tournament and the FIDE Women's World Championship Match. The first event in which Establishment Labs will be a partner is the FIDE Women's World Team Chess Championship, which kicked off on Sunday, September 26 in Sitges, Spain. 

 "One in eight women will develop breast cancer in her lifetime, and in most of the world, the number of women receiving a breast reconstruction is less than 10% with waiting times as long as eight years," said Dana Reizniece-Ozola, FIDE's Managing Director. "Many women undergo mastectomies as part of their treatment. Though lifesaving in many cases, a mastectomy may cause cancer survivors to feel mournful after losing an essential part of their body. Breast reconstruction is not only about repairing physical damage but also about repairing and even preventing psychological trauma. At FIDE, we value Establishment Labs' commitment to women's health and wellbeing. The company supports expanded access to breast reconstruction and has been a pioneer in offering technologies that can improve the outcomes for these women. We are grateful for their sponsorship."

Establishment Labs embraces several international sustainability standards in its business practices, including the United Nations Sustainable Development Goals (SDGs) and the Women's Empowerment Principles to promote gender equality and women's empowerment. The company also supports breast health programs and quality breast reconstruction initiatives in a number of countries. All of these activities are part of the company's purpose as a global corporate citizen: "Putting Women First: in health and wellbeing, science and technology, and our communities."

Please visit the Establishment Labs' website for additional information at www.establishmentlabs.com and motiva.health.